| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $153.4M | +94.1% |
| SG&A Expense | $24.2M | +58.0% |
| Operating Income | -$177.5M | -88.2% |
| Net Income | -$166.3M | -106.6% |
| EPS (Basic) | -$4.32 | -68.8% |
| EPS (Diluted) | -$4.32 | -68.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $45.5M | -38.7% |
| Short-term Investments | $267.3M | +84.9% |
| Current Assets | $332.9M | +46.7% |
| Total Assets | $333.2M | +21.2% |
| Current Liabilities | $25.9M | +50.2% |
| Total Liabilities | $25.9M | +50.1% |
| Stockholders' Equity | $307.2M | +19.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$160.6M | -128.7% |
| Investing Cash Flow | -$71.2M | +63.0% |
| Financing Cash Flow | $203.1M | +8.8% |